Group 1 - BeOne Medicines AG (NASDAQ:ONC) is recognized as a high growth international stock, with a Buy rating and a price target of $414 from Bernstein and $394 from Barclays [1][2][4] - The company received the first-in-world approval for its drug Sonrotoclax in China, aimed at treating relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) [2][4] - The MCL study showed a 52.4% overall response rate (ORR) and the CLL/SLL study demonstrated a 77% ORR, indicating strong efficacy of Sonrotoclax [4] Group 2 - Management emphasizes that the approval in China is part of a global rollout strategy for BeOne Medicines AG [4] - Bernstein's Rebecca Liang believes the company's pipeline is undervalued and highlights Sonrotoclax as having potential best-in-class status [4] - BeOne Medicines AG is a global oncology company focused on innovative cancer treatments for hematology and solid tumors [4]

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) has shown a slight decline of 0.30% in its closing price, with a trading volume of 2.32 billion yuan on February 13, 2025. The fund has experienced growth in both its share count and total assets since the beginning of the year [1]. Fund Overview - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) was established on March 26, 2025, with an annual management fee of 0.40% and a custody fee of 0.07%. Its performance benchmark is the adjusted return of the National Index for Hong Kong Stock Connect Innovative Drugs [1]. - As of February 12, 2025, the fund's latest share count is 3.935 billion shares, with a total asset size of 5.214 billion yuan. Compared to December 31, 2025, the fund's shares have increased by 4.57% and its total assets by 9.73% [1]. Liquidity - Over the last 20 trading days, the cumulative trading amount for the Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) reached 7.823 billion yuan, with an average daily trading amount of 391 million yuan [1]. Fund Management - The current fund managers are Liu Weilin and Jiao Wendong. Liu has managed the fund since March 26, 2025, achieving a return of 31.76%, while Jiao has been managing it since April 10, 2025, with a return of 50.17% [2]. Top Holdings - The fund's top holdings include: - CSPC Pharmaceutical Group (石药集团) - 10.65% of the portfolio, valued at 506 million yuan - BeiGene (百济神州) - 10.10%, valued at 480 million yuan - CanSino Biologics (康方生物) - 9.91%, valued at 471 million yuan - China National Pharmaceutical Group (中国生物制药) - 9.85%, valued at 468 million yuan - Innovent Biologics (信达生物) - 9.72%, valued at 462 million yuan - 3SBio (三生制药) - 7.08%, valued at 337 million yuan - Hansoh Pharmaceutical (翰森制药) - 7.07%, valued at 336 million yuan - Kelun Pharmaceutical (科伦博泰生物-B) - 3.54%, valued at 168 million yuan - Kangzhe Pharmaceutical (康哲药业) - 2.60%, valued at 124 million yuan [3].

Core Insights - The company Baiaosaitu-B (02315) has reported impressive performance forecasts, with significant progress in external licensing collaborations, leading institutions to be optimistic about its long-term growth potential [1] Financial Performance - For the fiscal year 2025, the company anticipates revenue between 1.369 billion and 1.389 billion yuan, representing a year-on-year growth of 39.61% to 41.65% [2] - The expected net profit attributable to shareholders is projected to be between 162 million and 182 million yuan, showing a substantial year-on-year increase of 384.26% to 443.88% [2] Business Developments - Since 2025, the company has secured significant external licensing agreements with leading domestic and international pharmaceutical companies, including a global licensing agreement for antibody molecules with BeiGene in July 2025 and full human antibody licensing for the RenMice platform with Merck in September 2025 [3] - These licensing agreements are expected to generate milestone payments and contribute to future growth [3] Institutional Perspectives - Research reports from institutions such as Guolian Minsheng Securities highlight the company's innovative advantages in model animals and preclinical CRO business, along with the "Thousand Mice, Ten Thousand Antibodies" initiative, which is expected to drive outstanding performance and open up long-term growth potential through external licensing [4] Stock Performance - The company was added to the Hong Kong Stock Connect eligible securities list on December 24, 2025, which may enhance investor attention and trading activity [5]

Core Viewpoint - The Hong Kong stock market is experiencing two distinct but resonant waves of incremental capital from mainland China and South Korean retail investors, leading to a diversification of funding sources and a layered pricing logic in the market [1][14]. Group 1: Scale and Structure - Southbound funds have established themselves as the core incremental source and revaluation force in the Hong Kong stock market, with a cumulative net inflow of 5.11 trillion HKD by the end of 2025, and a record annual net purchase of 1.41 trillion HKD in 2025 [2]. - The market capitalization of southbound funds has surpassed 6.3 trillion HKD, accounting for 12.7% of the total market capitalization of Hong Kong stocks, indicating their evolution into an "endogenous pricing variable" [2]. Group 2: Trading Behavior of South Korean Retail Investors - South Korean retail investors, while having a relatively limited capital size, exhibit highly concentrated and leveraged trading behaviors, particularly impacting specific sectors such as new economy IPOs and the semiconductor industry [5]. - In early 2026, South Korean retail investors made a net purchase of over 2 million USD in MiniMax-WP, contributing significantly to its IPO, which saw an oversubscription of 1837 times [5]. Group 3: Industry Preferences - Southbound funds focus on financials and high-dividend utilities, with significant investments in companies like China Construction Bank and China Mobile, driven by high dividend yields and low valuation levels [6]. - South Korean investors, on the other hand, show a preference for high-growth sectors, with notable investments in Xiaomi and MiniMax-WP, reflecting a narrative-driven trading strategy [8]. Group 4: Investment Strategies - Southbound funds demonstrate a long-term investment strategy characterized by stable holdings and systematic increases in positions, as seen with China Construction Bank, which saw a net purchase of 7.39 billion shares in 2025 [12]. - South Korean retail investors engage in high-frequency trading with a focus on social media trends and community consensus, leading to a rapid turnover of holdings, with an average holding period of less than three months [13]. Group 5: Market Dynamics - The influx of South Korean retail investors into the Hong Kong market represents a diversification of the investor base, contributing to liquidity while also potentially increasing volatility during certain periods [14]. - The interaction between the long-term positioning of southbound funds and the short-term trading strategies of South Korean investors creates a new normal in the Hong Kong stock market characterized by layered pricing and concurrent narratives [14].

Investment Rating - The report assigns a "Buy" rating for Alibaba Health, with a target price of HKD 7.39 per share [7]. Core Insights - The main business of Alibaba Health is experiencing accelerated growth, driven by the online penetration of innovative drugs and the integration of AI technologies, which present new opportunities for the company [7]. - The self-operated revenue of Alibaba Health has significantly increased, accounting for nearly 90% of total revenue, with a year-on-year growth of 19% to RMB 14.38 billion [7]. - The company is also the largest online B2C healthcare product retail platform in China, benefiting from deep collaboration with the Alibaba Group [7]. Summary by Sections Medical E-commerce Tracking - The online pharmacy market share is rapidly increasing, with innovative drugs driving growth. The retail pharmacy share has risen to 31.5%, while online pharmacies have reached 5.3% [14][15]. - The demand for original research drugs is increasing, with a shift towards online channels due to convenience and service [15][16]. Alibaba Health - The self-operated business is the main driver of revenue growth, with a 99% year-on-year increase in self-operated SKUs to 1.61 million [7]. - The company is enhancing its advertising capabilities, which will contribute significantly to profitability [7]. - AI technologies are expected to empower the main business, with initiatives like the "Qianwen Super Agent" and the medical AI assistant "Hydrogen Ion" app being developed [7]. Profit Forecast and Valuation - Revenue forecasts for fiscal years 2026 and 2027 are RMB 34.594 billion and RMB 38.235 billion, respectively, with adjusted net profits of RMB 2.499 billion and RMB 3.026 billion [2][7].

Group 1 - Korean investors have shown increasing enthusiasm for Chinese assets, with a total investment exceeding $88 million in the top ten stocks as of February 10, 2026 [3] - The top ten stocks purchased by Korean investors include MINIMAX-WP, Huaxia CSI 300 ETF, and Lanke Technology, with respective investments of $20.67 million, $19.18 million, and $18.64 million [1][2] - There is a noticeable shift in Korean investment focus towards emerging technology companies in China, compared to 2025, where the top investments were in companies like Xiaomi and Alibaba [4] Group 2 - The investment amounts for the top ten stocks in 2026 are as follows: MINIMAX-WP ($20.67 million), Huaxia CSI 300 ETF ($19.18 million), Lanke Technology ($18.64 million), and others, indicating a diverse interest in various sectors [2][4] - In 2025, the top investments were led by Xiaomi Group ($87.75 million) and Global X China Semiconductor ETF ($7.40 million), highlighting a different investment landscape compared to 2026 [5]

Financial Performance Announcement - The company, BeiGene, has announced that it will release its financial results for the fourth quarter and full year of 2025 on February 26, 2026, after the Hong Kong Stock Exchange trading hours [1][2] - The board of directors will review and approve the financial results on the same day [2] - A conference call will be held on February 26, 2026, at 8:00 AM Eastern Time (9:00 PM Hong Kong Time) to discuss the results, which will be available for investors to participate via the company's website [2] - The company expects to publish its audited annual results for 2025 by March 31, 2026, or earlier, in accordance with Hong Kong listing rules [2]

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report highlights that the recent national procurement has been stable, with limited disruptions, and institutions are increasing their positions in innovative companies, maintaining a positive outlook on undervalued innovative targets [1][4] - The overall market sentiment has improved, driven by significant business development transactions, and the pharmaceutical sector is expected to continue its steady growth in 2026, despite potential short-term volatility [4][5] Summary by Sections Market Performance - The Hang Seng Index rose by 1.3% and the Hang Seng Healthcare Index increased by 5.0%, ranking second among 12 industry indices [4][6] - Sub-sectors such as biopharmaceuticals and CXO both saw a growth of 7.4% [6] Institutional Holdings - Since Q4 2025, the proportion of domestic capital holding pharmaceutical stocks through Hong Kong Stock Connect has slightly decreased, while foreign capital holdings have increased [32] - As of February 10, 2026, domestic holdings were at 22.2%, down 0.2 percentage points, while foreign holdings rose to 39.7%, up 0.9 percentage points [32] Sales Performance - In 2025, China's pharmaceutical market sales decreased by 1% year-on-year, with public hospitals accounting for the largest market share at 10,977 billion RMB, down 2.1% [5] - Retail pharmacy sales reached 5,878 billion RMB, growing by 2.4%, with online pharmacies seeing a significant increase of 13.6% [5] National Procurement - The recent national procurement round had a high selection rate of 93%, with 1,020 products from 1,091 participating companies expected to be implemented by the end of March 2026 [5] - The procurement process has seen increased participation and a diverse range of selected products, ensuring stability in clinical demand [5] Investment Recommendations - The report recommends focusing on innovative drugs, particularly companies like Sanofi and Hengrui Medicine, which have rich catalysts and clear long-term growth logic [4] - It also suggests looking into CXO companies benefiting from high downstream demand and improving financing conditions, such as WuXi AppTec [4]

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report highlights that the recent national procurement has been stable, with a high selection rate of 93%, indicating a positive outlook for innovative companies in the sector [4][5] - The market sentiment has improved, driven by significant business development (BD) transactions, suggesting a continuation of the positive trend in 2026 despite potential short-term volatility [4] - The report emphasizes the importance of focusing on fundamentals and valuations when selecting stocks, particularly undervalued innovative companies that have been overlooked during market fluctuations [4] Summary by Sections Market Performance - The Hang Seng Index rose by 1.3% and the Hang Seng Healthcare Index increased by 5.0%, outperforming the broader market [4][6] - Sub-sectors such as biopharmaceuticals and CXO both saw a growth of 7.4% [6] Institutional Holdings - As of February 10, 2026, domestic institutional holdings through Hong Kong Stock Connect slightly decreased to 22.2%, while foreign holdings increased to 39.7%, indicating a shift towards more positive sentiment among foreign investors [32] - Key increases in holdings were noted in leading CXO companies benefiting from demand recovery, such as Tigermed and WuXi AppTec [37][38] Valuation Overview - The report provides a valuation summary for various companies, with notable buy ratings for AstraZeneca, BeiGene, and others, indicating strong growth potential [3] - The average price-to-earnings (P/E) ratio for the healthcare sector is reported at 28.4 times, with specific segments like biopharmaceuticals at 13.1 times [16] Sales Trends - The report notes a 1% year-on-year decline in China's pharmaceutical market sales for 2025, with significant variations across different sales channels [5] - Public hospitals accounted for the largest market share but experienced a 2.1% decline, while retail pharmacies saw a 2.4% increase, driven by online sales growth [5] Procurement Insights - The recent national procurement round involved 316 commonly used drugs, with a high participation rate and diverse product offerings, ensuring stable clinical supply [5] - The procurement process has been refined to enhance quality and reliability, with stricter requirements for participating companies [5]

Core Insights - 2025 marks a milestone year for China's innovative pharmaceuticals, with a significant increase in the number of approved drugs and vaccines, driven by supportive policies, international expansion, and expedited review processes [1][2] Group 1: Drug Approvals and Market Trends - In 2025, China approved 76 innovative drugs, surpassing the 48 approved in 2024, setting a historical record [1] - The number of approved innovative drugs in China exceeded that of the US FDA, which approved 46 new drugs in the same year [1] - China saw the approval of 11 First-in-class drugs, with 4 being independently developed domestically [1] - The total value of licensing transactions for innovative drugs exceeded $130 billion, with over 150 deals made, marking another historical high [1] Group 2: Breakthrough Therapies and Innovations - Among the 76 approved drugs, 17 were recognized as breakthrough therapies, with 13 focused on oncology [2] - Notable drug launches included the first stem cell therapy in China, marking a historic breakthrough in stem cell treatment [2] - The launch of targeted HER2 drugs for non-small cell lung cancer and cholangiocarcinoma signifies a new phase in precision treatment for solid tumors in China [2] Group 3: Disease-Specific Developments - In oncology, 34 new drugs were approved, with breast cancer treatments leading at 9 new drugs, followed by 6 for lung cancer and 8 for hematological malignancies [3] - Two CAR-T cell therapies targeting CD19 were approved, bringing the total number of domestic CAR-T therapies to 7 [3] Group 4: Innovations in Other Therapeutic Areas - In the influenza treatment sector, four new drugs were launched, addressing public health needs during peak flu seasons [4] - The innovative vaccine sector saw significant advancements, including the launch of China's first nine-valent HPV vaccine and a 13-valent pneumococcal conjugate vaccine [5] - The emergence of a serum-free rabies vaccine is expected to fill a market gap, showcasing China's growing capabilities in biopharmaceutical innovation [5]